{"componentChunkName":"component---src-templates-chapter-level-2-chapter-level-2-tsx","path":"/topics/chilblains/prescribing-information/nifedipine/","result":{"pageContext":{"chapter":{"id":"b6be7c9c-cf67-5a2d-abb4-b8edc8d404e9","slug":"nifedipine","fullItemName":"Nifedipine","depth":2,"htmlHeader":"<!-- begin field 473ef787-7eae-4162-a24c-d569b40db941 --><h2>Nifedipine</h2><!-- end field 473ef787-7eae-4162-a24c-d569b40db941 -->","summary":"","htmlStringContent":"<!-- begin item c042662f-3c6d-4754-a3bc-c8891f0a31bf --><!-- begin field 69415826-6f42-4901-81c8-41834193fe97 --><p>The use of nifedipine in the treatment and prophylaxis of chilblains is off-label and the evidence to support its use is based on limited small studies — for more information see the <a class=\"topic-reference internal-reference\" href=\"/topics/chilblains/management/management/#basis-for-recommendation-829\">Basis for recommendation</a> section.</p><p><strong>Contraindications and cautions</strong> [<a class=\"bibliography-reference internal-reference\" href=\"/topics/chilblains/references/\">ABPI, 2017</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/chilblains/references/\">BNF 75, 2018</a>]</p><ul><li><strong>Do not prescribe nifedipine:</strong><ul><li>To people with known hypersensitivity to nifedipine, other dihydropyridines (theoretical risk of cross-reactivity) or any of the excipients.</li><li>To people with unstable angina, cardiogenic shock, significant aortic stenosis, unstable angina, or within 1 month of myocardial infarction.</li><li>To women who are pregnant or breastfeeding — seek specialist advice if these women require treatment.</li><li>To children under the age of 18 years — safety in children has not been established.</li><li>To people taking rifampicin. Rifampicin induces the cytochrome P450 system —bioavailability of nifedipine will be markedly reduced, the manufacturer advises avoid.</li></ul></li><li><strong>Nifedipine should be prescribed with caution in:</strong><ul><li>People with heart failure, poor cardiac reserve, hypotension or significantly impaired left ventricular function.</li><li>The elderly — pharmacokinetics are altered in the older people so that lower doses may be required.</li><li>Diabetes mellitus — may affect glycaemic control.</li><li>People with a history of oesophageal or gastro-intestinal obstruction, decreased lumen diameter of the gastro-intestinal tract, or inflammatory bowel disease (including Crohn's disease) — some formulations should be avoided, check the individual product literature.</li><li>Hepatic impairment — nifedipine is metabolised primarily by the liver. Certain preparations are contraindicated in hepatic impairment.</li></ul></li></ul><p><strong>Adverse effects </strong>[<a class=\"bibliography-reference internal-reference\" href=\"/topics/chilblains/references/\">ABPI, 2017</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/chilblains/references/\">BNF 75, 2018</a>]</p><ul><li>Common or very common — asthenia; dizziness; gastro-intestinal disturbance (including constipation); headache; hypotension; lethargy; oedema (including peripheral oedema); palpitation; vasodilatation.<ul><li>Short-acting formulations may be associated with large variations in blood pressure and reflex tachycardia.</li></ul></li><li>Uncommon — angioedema; anxiety; chills; dyspnoea; dysuria; epistaxis; erectile dysfunction; hypersensitivity reactions; jaundice; joint swelling; migraine; myalgia; nasal congestion; nocturia; paraesthesia; polyuria; pruritus; rash; sleep disturbance; sweating; syncope; tachycardia; tremor; urticaria; vertigo; visual disturbance.<ul><li>Cardiac ischaemic pain has been reported, in a small proportion of people, after taking nifedipine — discontinue treatment if this occurs.</li></ul></li><li>Rare — anorexia; gum hyperplasia; hyperglycaemia; male infertility; mood disturbances; photosensitivity reactions; purpura.</li><li>Frequency not known — agranulocytosis; anaphylaxis; bezoar formation (with some modified-release preparations); dysphagia; gynaecomastia; intestinal obstruction; intestinal ulcer.</li></ul><p><strong>Drug interactions </strong>[<a class=\"bibliography-reference internal-reference\" href=\"/topics/chilblains/references/\">ABPI, 2017</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/chilblains/references/\">BNF 75, 2018</a>]</p><ul><li>Nifedipine is metabolised via the cytochrome P450 3A4 system. Drugs that are known to either inhibit or to induce this enzyme system may therefore alter the first pass or the clearance of nifedipine.<ul><li>Cytochrome P450 inhibitors (such as macrolide antibiotics [for example erythromycin], anti-HIV protease inhibitors [for example ritonavir], azole antimycotics [for example ketoconazole], some antidepressants [nefazodone and fluoxetine], valproic acid, diltiazem, cimetidine and grapefruit juice) may lead to increased plasma concentrations of nifedipine.</li><li>Cytochrome P450 inducers (such as rifampicin [avoid], phenytoin, carbamazepine, and phenobarbital) may lead to reduced plasma concentrations of nifedipine.</li></ul></li><li>Mefloquine — may increase the risk of bradycardia when given with nifedipine.</li><li>Concomitant antihypertensives — increased blood pressure lowering effect.</li><li>Beta-blockers — deterioration of heart failure has developed in isolated cases.</li><li>Digoxin — may lead to reduced digoxin clearance and an increase in the plasma digoxin level.</li></ul><p><strong>Additional prescribing and dispensing information</strong></p><ul><li>As different versions of modified-release preparations may not have the same clinical effect, the British National Formulary [<a class=\"bibliography-reference internal-reference\" href=\"/topics/chilblains/references/\">BNF 75, 2018</a>] recommends that prescribers specify the specific brand to be dispensed.</li></ul><!-- end field 69415826-6f42-4901-81c8-41834193fe97 --><!-- end item c042662f-3c6d-4754-a3bc-c8891f0a31bf -->","topic":{"id":"98f988ea-4ee8-52e9-8212-438a79499f92","topicId":"17adddaf-c9b6-4278-9b49-932d14f56439","topicName":"Chilblains","slug":"chilblains","lastRevised":"Last revised in June 2018","chapters":[{"id":"541e07aa-8e84-55e1-817f-8d101eeb46fd","fullItemName":"Summary","slug":"summary","subChapters":[]},{"id":"e6b34a51-a690-5858-9a53-0dc5d5b0e608","fullItemName":"Have I got the right topic?","slug":"have-i-got-the-right-topic","subChapters":[]},{"id":"5f3bae74-0385-5bf1-b250-9e74f16cfe18","fullItemName":"How up-to-date is this topic?","slug":"how-up-to-date-is-this-topic","subChapters":[{"id":"4ae9419d-bc20-56ba-91a1-0420a339c087","slug":"changes","fullItemName":"Changes"},{"id":"e57dda70-8cbd-58d2-a2fb-8901c08e6853","slug":"update","fullItemName":"Update"}]},{"id":"ddec423e-57a6-54df-ba06-4014b41b839c","fullItemName":"Goals and outcome measures","slug":"goals-outcome-measures","subChapters":[{"id":"9315120c-762a-5273-867b-759b5537e4b8","slug":"goals","fullItemName":"Goals"},{"id":"666bca6f-0132-53bc-95cc-27fcbd0b4a96","slug":"outcome-measures","fullItemName":"Outcome measures"},{"id":"8b7e8a8e-c9dd-5555-8409-dfea005ea395","slug":"audit-criteria","fullItemName":"Audit criteria"},{"id":"fa795717-6d81-577e-b792-90e487b3895c","slug":"qof-indicators","fullItemName":"QOF indicators"},{"id":"bff6f393-7347-51fa-8d46-95b80a272b9e","slug":"qipp-options-for-local-implementation","fullItemName":"QIPP - Options for local implementation"},{"id":"7da4aff5-e153-5f3f-bc51-0a943110c08d","slug":"nice-quality-standards","fullItemName":"NICE quality standards"}]},{"id":"1cc6d520-d1d7-5bcd-9d7c-b1352c82d453","fullItemName":"Background information","slug":"background-information","subChapters":[{"id":"bba6260f-6b68-52b5-88c0-17f3ba449705","slug":"definition","fullItemName":"Definition"},{"id":"f4b6f42f-60f1-56db-9cc2-c9d377ec6c5a","slug":"causes","fullItemName":"Causes"},{"id":"adb617b9-5304-53c4-8f1f-6aaec8a9c35b","slug":"prevalence","fullItemName":"Prevalence"},{"id":"16008222-9ac8-5d8e-9380-55d21f8ca4d9","slug":"complications","fullItemName":"Complications"},{"id":"16a3612e-723d-580a-a4c7-157274078ba8","slug":"prognosis","fullItemName":"Prognosis"}]},{"id":"4c9a7bb6-deca-5726-8c77-5c4cc1bfa2a1","fullItemName":"Diagnosis","slug":"diagnosis","subChapters":[{"id":"468b6d0a-7e5f-59c0-affa-b0ee0c6eec91","slug":"clinical-features","fullItemName":"Clinical features"},{"id":"08c8ac64-d612-5dfe-9926-2d0dfbc02f14","slug":"assessment","fullItemName":"Assessment"},{"id":"3db0f33f-97a0-5db2-83b8-ca9bb0e25bdc","slug":"differential-diagnosis","fullItemName":"Differential diagnosis"}]},{"id":"ae9e38d9-23ba-50f8-8fd8-949711f14be6","fullItemName":"Management","slug":"management","subChapters":[{"id":"757e5e29-3beb-57b4-b55c-3050dd84bdc8","slug":"management","fullItemName":"Scenario: Management"}]},{"id":"7f12498b-880e-5fca-908a-0c9547ba0d60","fullItemName":"Prescribing information","slug":"prescribing-information","subChapters":[{"id":"b6be7c9c-cf67-5a2d-abb4-b8edc8d404e9","slug":"nifedipine","fullItemName":"Nifedipine"}]},{"id":"c98234ab-a54f-5b11-bd3d-ddc791a382d6","fullItemName":"Supporting evidence","slug":"supporting-evidence","subChapters":[]},{"id":"1c4fbb70-40dc-5931-9e8e-6d8fdcd80db4","fullItemName":"How this topic was developed","slug":"how-this-topic-was-developed","subChapters":[{"id":"a6193060-7713-5e53-9336-66e3cb961a3a","slug":"search-strategy","fullItemName":"Search strategy"},{"id":"c1d12d25-39b2-5827-a25e-dcf5536bf470","slug":"stakeholder-engagement","fullItemName":"Stakeholder engagement"},{"id":"435de6c9-1336-5c37-8c94-8ab2ee7f2adb","slug":"evidence-exclusion-criteria","fullItemName":"Evidence exclusion criteria"},{"id":"cc4fe9b8-3554-5630-88cd-6dfee9d06235","slug":"organizational-behavioural-financial-barriers","fullItemName":"Organizational, behavioural and financial barriers"},{"id":"2d1b809a-3a66-5daa-a184-7cdfb748fe77","slug":"declarations-of-interest","fullItemName":"Declarations of interest"}]},{"id":"d01450d0-bab3-5fff-9ec6-40623a484024","fullItemName":"References","slug":"references","subChapters":[]}]},"parentChapter":{"id":"7f12498b-880e-5fca-908a-0c9547ba0d60","slug":"prescribing-information","fullItemName":"Prescribing information"},"subChapters":[]}}},"staticQueryHashes":["3666801979"]}